Rheumatic fever is an inflammatory disorder caused by a Group A strep throat infection. It affects the connective tissue of the body, causing temporary, painful arthritis and other symptoms.
In some cases rheumatic fever causes long-term damage to the heart and its valves. This is called rheumatic heart disease.
Rheumatic fever occurs as a result of a rare strain of strep throat that isn’t treated with antibiotics quickly enough or at all. Doctors aren’t sure why this rare strain of strep triggers this inflammatory disorder. It’s probably because antibodies (special proteins in the blood that attack strep) mistakenly also attack healthy cells, such as the heart muscle and valve cells, as well as joint, brain and skin tissue, causing a reaction that results in inflammation.
Strep throat is most common in school-aged children, and so is rheumatic fever. Rheumatic fever was a leading cause of disability and death in children in the United States before 1960. Today, rheumatic fever is not common in the United States because most people have access to penicillin and other antibiotics. However, it does still occur in this country and remains a leading cause of early death in countries with less-developed healthcare systems.
There is also a genetic factor in rheumatic fever. The members of some families are much more likely to develop it, and researchers are currently looking to understand why.
Rheumatic fever can cause:
- Carditis: inflammation of the heart muscle and heart tissue. Carditis can cause a rapid heart rate, fatigue, shortness of breath and exercise intolerance. This is the most serious of the symptoms and may have long-term effects on health. Carditis occurs in approximately 50 percent of those who have rheumatic fever
- Arthritis: swelling, redness and pain in the joints, especially knees, ankles, elbows and wrists. This is a common symptom and occurs in approximately 70 percent of people who have rheumatic fever
- Splotchy rash that doesn’t itch
- Subcutaneous nodules: tiny, hard lumps under the skin
- Fever
- Chorea: involuntary movement of the extremities. This is more common in females (previously called “St. Vita’s dance”)
There is no single test to diagnose rheumatic fever. Your child's doctor may use the modified Jones criteria to determine if your child has rheumatic fever. A child must show evidence of a prior strep infection through throat culture or blood work, as well as labs that show inflammation in the body. These tests, combined with other physical findings and signs of heart involvement, help doctors make the diagnosis.
Your child’s doctor may also order an electrocardiogram (ECG) and/or an echocardiogram (ultrasound of the heart). An ECG is done to look for abnormal electrical conduction through the heart; an echocardiogram is done to look for leaking heart valves, fluid in the sac around the heart or poor heart muscle function.
Penicillin, aspirin and other medicines are used to treat rheumatic fever. Children will also have to stay on a low dose of penicillin for years to reduce the risk of recurrence. It's very important to prevent a recurrence because of the risk of more damage to the heart.
Carditis, or inflammation of the heart muscle and tissue, is the most serious result of rheumatic fever. Some children don’t develop carditis while others develop mild carditis that may not cause problems in the future.
For children who do develop severe carditis, the inflammation leads to scarring and permanent damage to the heart, and particularly to the heart valves. The mitral valve, which controls the flow of blood between the upper left chamber and the lower left chamber of the heart, is most often damaged. The aortic valve, which sends the blood from the left lower chamber out to the body, is the next most commonly affected heart valve. Leakage of the heart valves is the most common finding.
In later years, blockage of the mitral valve can occur due to scarring. If either valve starts to leak severely, surgery to repair or replace it may be necessary. Usually this isn’t necessary before adulthood, but in severe cases, surgery during youth is necessary.
Children and teens who have serious rheumatic heart disease will need to see a cardiologist regularly for the rest of their lives. The doctor will monitor heart function so that if problems develop, they can be addressed as quickly as possible.
1. Gewitz MH, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131:1806–1818. The 2015 revision of the Jones Criteria provides, for the first time, differing criteria for low and high disease incidence settings. [PubMed] [Google Scholar]
2. Denny FW, Wannamaker LW, Brink WR, Rammelkamp CH, Jr, Custer E. A Prevention of rheumatic fever; treatment of the preceding streptococcic infection. J Am Med Assoc. 1950;143:151–153. [PubMed] [Google Scholar]
3. Stollerman GH, Rusoff JH, Hirschfeld I. Prophylaxis against group A streptococci in rheumatic fever; the use of single monthly injections of benzathine penicillin G. N Engl J Med. 1955;252:787–792. [PubMed] [Google Scholar]
4. Carapetis JR. The stark reality of rheumatic heart disease. Eur Heart J. 2015;36:1070–1073. [PubMed] [Google Scholar]
5. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. Rev Infect Dis. 1989;11:928–953. This paper describes the first attempt to quantify the global disease burden resulting from ARF. Although the estimates did not incorporate many data from developing countries, this paper set the scene for subsequent disease burden estimates. [PubMed] [Google Scholar]
6. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–694. This article outlines the most definitive attempt to quantify the global disease burden due to GAS infections, including ARF and RHD. This study proved to be pivotal for advocacy efforts and also highlighted major gaps in data, particularly from developing countries. [PubMed] [Google Scholar]
7. Murray CJ, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. [PubMed] [Google Scholar]
8. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. [PMC free article] [PubMed] [Google Scholar]
9. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. The GBD study has attempted to update RHD burden estimates, and this is one of many papers from that study. The methodology continues to be refined, so estimates are still not sufficiently robust, but most researchers in the RHD community believe the GBD estimates are moving us closer to understanding the true burden of RHD. [PMC free article] [PubMed] [Google Scholar]
10. Lawrence JG, Carapetis JR, Griffiths K, Edwards K, Condon JR. Acute rheumatic fever and rheumatic heart disease: incidence and progression in the Northern Territory of Australia, 1997 to 2010. Circulation. 2013;128:492–501. [PubMed] [Google Scholar]
11. Parnaby MG, Carapetis JR. Rheumatic fever in indigenous Australian children. J Paediatr Child Health. 2010;46:527–533. [PubMed] [Google Scholar]
12. Rothenbuhler M, et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. Lancet Glob Health. 2014;2:e717–e726. [PubMed] [Google Scholar]
13. Yacoub Wasef SZ. Gender differences in systemic lupus erythematosus. Gend Med. 2004;1:12–17. [PubMed] [Google Scholar]
14. Diao M, et al. Pregnancy in women with heart disease in sub-Saharan Africa. Arch Cardiovasc Dis. 2011;104:370–374. [PubMed] [Google Scholar]
15. Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–e333. [PubMed] [Google Scholar]
16. Soma-Pillay P, MacDonald AP, Mathivha TM, Bakker JL, Mackintosh MO. Cardiac disease in pregnancy: a 4-year audit at Pretoria Academic Hospital. S Afr Med J. 2008;98:553–556. [PubMed] [Google Scholar]
17. Sawhney H, et al. Maternal and perinatal outcome in rheumatic heart disease. Int J Gynaecol Obstetr. 2003;80:9–14. [PubMed] [Google Scholar]
18. Steer AC, Carapetis JR, Nolan TM, Shann F. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health. 2002;38:229–234. [PubMed] [Google Scholar]
19. Brown A, McDonald MI, Calma T. Rheumatic fever and social justice. Med J Aust. 2007;186:557–558. [PubMed] [Google Scholar]
20. Riaz BK, et al. Risk factors of rheumatic heart disease in Bangladesh: a case–control study. J Health Popul Nutr. 2013;31:70–77. [PMC free article] [PubMed] [Google Scholar]
21. Quinn RW. Epidemiology of group A streptococcal infections — their changing frequency and severity. Yale J Biol Med. 1982;55:265–270. [PMC free article] [PubMed] [Google Scholar]
22. Jaine R, Baker M, Venugopal K. Acute rheumatic fever associated with household crowding in a developed country. Pediatr Infect Dis J. 2011;30:315–319. [PubMed] [Google Scholar]
23. Okello E, et al. Socioeconomic and environmental risk factors among rheumatic heart disease patients in Uganda. PLoS ONE. 2012;7:e43917. [PMC free article] [PubMed] [Google Scholar]
24. Carapetis JR, Currie BJ. Rheumatic fever in a high incidence population: the importance of monoarthritis and low grade fever. Arch Dis Child. 2001;85:223–227. [PMC free article] [PubMed] [Google Scholar]
25. Gordis L. Effectiveness of comprehensive-care programs in preventing rheumatic fever. N Engl J Med. 1973;289:331–335. [PubMed] [Google Scholar]
26. Bach JF, et al. 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Lancet. 1996;347:644–648. [PubMed] [Google Scholar]
27. Nordet P, Lopez R, Duenas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience. Cardiovasc J Afr. 2008;19:135–140. [PMC free article] [PubMed] [Google Scholar]
28. Omurzakova NA, et al. High incidence of rheumatic fever and rheumatic heart disease in the republics of Central Asia. Int J Rheum Dis. 2009;12:79–83. [PubMed] [Google Scholar]
29. Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor autoantibodies correlate with symptoms in Sydenham’s chorea. PLoS ONE. 2013;8:e73516. [PMC free article] [PubMed] [Google Scholar]
30. Brimberg L, et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology. 2012;37:2076–2087. [PMC free article] [PubMed] [Google Scholar]
31. Cox CJ, et al. Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease. J Immunol. 2013;191:5524–5541. [PMC free article] [PubMed] [Google Scholar]
32. Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol. 2014;33:314–329. [PMC free article] [PubMed] [Google Scholar]
33. Ellis NMJ, Li Y, Hildebrand W, Fischetti VA, Cunningham MW. T cell mimicry and epitope specificity of crossreactive T cell clones from rheumatic heart disease. J Immunol. 2005;175:5448–5456. [PubMed] [Google Scholar]
34. Fae KC, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol. 2006;176:5662–5670. References 33 and 34 outline the investigation of cross-reactive T cell clones from the blood and heart of patients with rheumatic carditis and describe the identification of T cell clone cross-reactivity with human cardiac myosin and the group A streptococcal M protein. [PubMed] [Google Scholar]
35. Galvin JE, Hemric ME, Ward K, Cunningham MW. Cytotoxic monoclonal antibody from rheumatic carditis reacts with human endothelium: implications in rheumatic heart disease. J Clin Invest. 2000;106:217–224. [PMC free article] [PubMed] [Google Scholar]
36. Husby G, van de Rijn I, Zabriskie JB, Abdin ZH, Williams RC. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med. 1976;144:1094–1110. [PMC free article] [PubMed] [Google Scholar]
37. Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham’s chorea. J Immunol. 2007;178:7412–7421. [PubMed] [Google Scholar]
38. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9:914–920. This study of human mAbs derived from Sydenham’s chorea showed that antibodies in chorea were cross-reactive with the group A carbohydrate antigen N-acetyl-β-D-glucosamine and brain antigens such as lysoganglioside and could alter signalling activity in human neuronal cell cultures. Together these data provided strong evidence for a role for cross-reactivity between group A streptococci and brain tissues and molecular mimicry in this manifestation of ARF. [PubMed] [Google Scholar]
39. Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham’s chorea. Autoimmunity. 2006;39:21–29. [PubMed] [Google Scholar]
40. Krisher K, Cunningham MW. Myosin: a link between streptococci and heart. Science. 1985;227:413–415. Using mAbs from mice immunized with group A streptococcal wall-membrane antigens, this study found that antibodies against the group A streptococci reacted with both heart and streptococcal antigens and that the target heart antigen was myosin. This study thus showed for the first time the roles of cross-reactivity and molecular mimicry in ARF. [PubMed] [Google Scholar]
41. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992;358:155–157. [PubMed] [Google Scholar]
42. Shikhman AR, Cunningham MW. Immunological mimicry between N-acetyl-beta-D-glucosamine and cytokeratin peptides. Evidence for a microbially driven anti-keratin antibody response. J Immunol. 1994;152:4375–4387. [PubMed] [Google Scholar]
43. Swerlick RA, Cunningham MW, Hall NK. Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin. J Invest Dermatol. 1986;87:367–371. [PubMed] [Google Scholar]
44. Stollerman GH. Rheumatic fever in the 21st century. Clin Infect Dis. 2001;33:806–814. [PubMed] [Google Scholar]
45. Veasy LG, et al. Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics. 2004;113:168–172. [PubMed] [Google Scholar]
46. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis. 2004;4:240–245. [PubMed] [Google Scholar]
47. Bessen DE, et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis. 2000;182:1109–1116. [PubMed] [Google Scholar]
48. Erdem G, et al. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis. 2007;45:e20–e24. [PubMed] [Google Scholar]
49. Smeesters PR, et al. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS ONE. 2006;1:e10. [PMC free article] [PubMed] [Google Scholar]
50. Steer AC, et al. Acute rheumatic fever and rheumatic heart disease in Fiji: prospective surveillance, 2005–2007. Med J Aust. 2009;190:133–135. [PubMed] [Google Scholar]
51. Potter EV, et al. Relationship of acute rheumatic fever to acute glomerulonephritis in Trinidad. J Infect Dis. 1972;125:619–625. [PubMed] [Google Scholar]
52. Zuhlke L, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study) Eur Heart J. 2015;36:1115–1122. [PMC free article] [PubMed] [Google Scholar]
53. Towers RJ, et al. Extensive diversity of Streptococcus pyogenes in a remote human population reflects global-scale transmission rather than localised diversification. PLoS ONE. 2013;8:e73851. [PMC free article] [PubMed] [Google Scholar]
54. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time. Susceptibility to acute rheumatic fever. Circulation. 2009;119:742–753. [PubMed] [Google Scholar]
55. Messias Reason IJ, Schafranski MD, Jensenius JC, Steffensen R. The association between mannose-binding lectin gene polymorphism and rheumatic heart disease. Hum Immunol. 2006;67:991–998. [PubMed] [Google Scholar]
56. Ramasawmy R, et al. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease 2 with chronic severe aortic regurgitation of rheumatic etiology. Clin Vaccine Immunol. 2008;15:932–936. [PMC free article] [PubMed] [Google Scholar]
57. Messias-Reason IJ, Schafranski MD, Kremsner PG, Kun JF. Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin Exp Immunol. 2009;157:395–399. [PMC free article] [PubMed] [Google Scholar]
58. Berdeli A, Celik HA, Ozyürek R, Dogrusoz B, Aydin HH. TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med (Berl) 2005;83:535–541. [PubMed] [Google Scholar]
59. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30:25–28. [PubMed] [Google Scholar]
60. Settin A, Abdel-Hady H, El-Baz R, Saber I. Gene polymorphisms of TNF-α−308, IL-10−1082, IL-6−174, and IL-1RaVNTR related to susceptibility and severity of rheumatic heart disease. Pediatr Cardiol. 2007;28:363–371. [PubMed] [Google Scholar]
61. Azevedo PM, et al. Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. Cytokine. 2010;49:109–113. [PubMed] [Google Scholar]
62. Hernández-Pacheco G, et al. Tumor necrosis factor-α promoter polymorphisms in Mexican patients with rheumatic heart disease. J Autoimmun. 2003;21:59–63. [PubMed] [Google Scholar]
63. Ramasawmy R, et al. Association of polymorphisms within the promoter region of the tumor necrosis factor-α with clinical outcomes of rheumatic fever. Mol Immunol. 2007;44:1873–1878. [PubMed] [Google Scholar]
64. Sallakci N, et al. TNFα G-308A polymorphism is associated with rheumatic fever and correlates with increased TNFα production. J Autoimmun. 2005;25:150–154. [PubMed] [Google Scholar]
65. Kamal H, et al. Transforming growth factor-β1 gene C-509T and T869C polymorphisms as possible risk factors in rheumatic heart disease in Egypt. Acta Cardiol. 2010;65:177–183. [PubMed] [Google Scholar]
66. Chou HT, Chen CH, Tsai CH, Tsai FJ. Association between transforming growth factor-β1 gene C-509T and T869C polymorphisms and rheumatic heart disease. Am Heart J. 2004;148:181–186. [PubMed] [Google Scholar]
67. Düzgün N, Duman T, Haydardedeog˘lu FE, Tutkak H. Cytotoxic T lymphocyte-associated antigen-4 polymorphism in patients with rheumatic heart disease. Tissue Antigens. 2009;74:539–542. [PubMed] [Google Scholar]
68. Maharaj B, Hammond MG, Appadoo B, Leary WP, Pudifin DJ. HLA-A, B, DR, and DQ antigens in black patients with severe chronic rheumatic heart disease. Circulation. 1987;76:259–261. [PubMed] [Google Scholar]
69. Monplaisir N, Valette I, Bach JF. HLA antigens in 88 cases of rheumatic fever observed in Martinique. Tissue Antigens. 1986;28:209–213. [PubMed] [Google Scholar]
70. Donadi EA, Smith AG, Louzada-Júnior P, Voltarelli JC, Nepom GT. HLA class I and class II profiles of patients presenting with Sydenham’s chorea. J Neurol. 2000;247:122–128. [PubMed] [Google Scholar]
71. Ayoub EM, Barrett DJ, Maclaren NK, Krischer JP. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest. 1986;77:2019–2026. [PMC free article] [PubMed] [Google Scholar]
72. Hernández-Pacheco G, et al. MHC class II alleles in Mexican patients with rheumatic heart disease. Int J Cardiol. 2003;92:49–54. [PubMed] [Google Scholar]
73. Jhinghan B, et al. HLA, blood groups and secretor status in patients with established rheumatic fever and rheumatic heart disease. Tissue Antigens. 1986;27:172–178. [PubMed] [Google Scholar]
74. Ozkan M, et al. HLA antigens in Turkish race with rheumatic heart disease. Circulation. 1993;87:1974–1978. [PubMed] [Google Scholar]
75. Anastasiou-Nana MI, Anderson JL, Carlquist JF, Nanas JN. HLA-DR typing and lymphocyte subset evaluation in rheumatic heart disease: a search for immune response factors. Am Heart J. 1986;112:992–997. [PubMed] [Google Scholar]
76. Rajapakse CN, Halim K, Al-Orainey I, Al-Nozha M, Al-Aska AK. A genetic marker for rheumatic heart disease. Br Heart J. 1987;58:659–662. [PMC free article] [PubMed] [Google Scholar]
77. Guilherme L, Weidenbach W, Kiss MH, Snitcowdky R, Kalil J. Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Circulation. 1991;83:1995–1998. [PubMed] [Google Scholar]
78. Visentainer JE, et al. Association of HLA-DR7 with rheumatic fever in the Brazilian population. J Rheumatol. 2000;27:1518–1520. [PubMed] [Google Scholar]
79. Guédez Y, et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation. 1999;99:2784–2790. [PubMed] [Google Scholar]
80. Stanevicha V, et al. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther. 2003;5:R340–R346. [PMC free article] [PubMed] [Google Scholar]
81. Olmez U, et al. Association of HLA class I and class II antigens with rheumatic fever in a Turkish population. Scand J Rheumatol. 1993;22:49–52. [PubMed] [Google Scholar]
82. Guilherme L, Köhler KF, Kalil J. Rheumatic heart disease: mediation by complex immune events. Adv Clin Chem. 2011;53:31–50. [PubMed] [Google Scholar]
83. Yoshinoya S, Pope RM. Detectioin of immune complexes in acute rheumatic fever and their relationship to HLA-B5. J Clin Invest. 1980;65:136–145. [PMC free article] [PubMed] [Google Scholar]
84. Kaplan MH, Bolande R, Ratika L, Blair J. Presence of bound immunoglobulins and complement in the myocardium in acute rheumatic fever. N Engl J Med. 1964;271:637. [PubMed] [Google Scholar]
85. Roberts S, et al. Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis. 2001;183:507–511. [PubMed] [Google Scholar]
86. Greenfield JG, Wolfson JM. The pathology of Sydenham’s chorea. Lancet. 1922;2:603–606. [Google Scholar]
87. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun. 2001;69:4072–4078. [PMC free article] [PubMed] [Google Scholar]
88. Taranta A, Stollerman GH. The relationship of Sydenham’s chorea to infection with group A streptococci. Am J Med. 1956;20:170–175. [PubMed] [Google Scholar]
89. Meador-Woodruff JH, et al. Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology. 1991;5:231–242. [PubMed] [Google Scholar]
90. Lotan D, et al. Behavioral and neural effects of intra-striatal infusion of anti-streptococcal antibodies in rats. Brain Behav Immun. 2014;38:249–262. [PMC free article] [PubMed] [Google Scholar]
91. Hoffman KL, Hornig M, Yaddanapudi K, Jabado O, Lipkin WI. A murine model for neuropsychiatric disorders associated with group A β-hemolytic streptococcal infection. J Neurosci. 2004;24:1780–1791. [PMC free article] [PubMed] [Google Scholar]
92. Perlmutter SJ, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive– compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153–1158. [PubMed] [Google Scholar]
93. Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham’s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol. 2005;20:424–429. [PubMed] [Google Scholar]
94. Barash J, Margalith D, Matitiau A. Corticosteroid treatment in patients with Sydenham’s chorea. Pediatr Neurol. 2005;32:205–207. [PubMed] [Google Scholar]
95. Cardoso F, Maia D, Cunningham MC, Valenca G. Treatment of Sydenham chorea with corticosteroids. Mov Disord. 2003;18:1374–1377. [PubMed] [Google Scholar]
96. Fusco C, Ucchino V, Frattini D, Pisani F, Della Giustina E. Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham’s chorea. Eur J Paediatr Neurol. 2012;16:373–378. [PubMed] [Google Scholar]
97. Paz JA, Silva CA, Marques-Dias MJ. Randomized double-blind study with prednisone in Sydenham’s chorea. Pediatr Neurol. 2006;34:264–269. [PubMed] [Google Scholar]
98. Walker AR, et al. Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids. J Pediatr. 2007;151:679–683. [PubMed] [Google Scholar]
99. Yaddanapudi K, et al. Passive transfer of streptococcus-induced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. Mol Psychiatry. 2009;15:712–726. [PubMed] [Google Scholar]
100. Lotan D, Cunningham M, Joel D. Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen. PLoS ONE. 2014;9:e101257. [PMC free article] [PubMed] [Google Scholar]
101. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13:470–511. [PMC free article] [PubMed] [Google Scholar]
102. Zabriskie JB. Mimetic relationships between group A streptococci and mammalian tissues. Adv Immunol. 1967;7:147–188. [PubMed] [Google Scholar]
103. Zabriskie JB, Freimer EH. An immunological relationship between the group A streptococcus and mammalian muscle. J Exp Med. 1966;124:661–678. [PMC free article] [PubMed] [Google Scholar]
104. Zabriskie JB, Hsu KC, Seegal BC. Heart-reactive antibody associated with rheumatic fever: characterization and diagnostic significance. Clin Exp Immunol. 1970;7:147–159. [PMC free article] [PubMed] [Google Scholar]
106. Goldstein I, Halpern B, Robert L. Immunological relationship between streptococcus A polysaccharide and the structural glycoproteins of heart valve. Nature. 1967;213:44–47. [Google Scholar]
107. Dudding BA, Ayoub EM. Persistence of streptococcal group A antibody in patients with rheumatic valvular disease. J Exp Med. 1968;128:1081–1098. [PMC free article] [PubMed] [Google Scholar]
108. McNamara C, et al. Coiled-coil irregularities and instabilities in group A streptococcus M1 are required for virulence. Science. 2008;319:1405–1408. [PMC free article] [PubMed] [Google Scholar]
109. Ellis NMJ, et al. Priming the immune system for heart disease: a perspective on group A streptococci. J Infect Dis. 2010;202:1059–1067. [PubMed] [Google Scholar]
110. Gorton DE, et al. Cardiac myosin epitopes for monitoring progression of rheumatic fever. Pediatr Infect Dis J. 2011;30:1015–1016. [PMC free article] [PubMed] [Google Scholar]
111. Cunningham MW, Antone SM, Smart M, Liu R, Kosanke S. Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun. 1997;65:3913–3923. [PMC free article] [PubMed] [Google Scholar]
112. Cunningham MW, et al. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J Immunol. 1989;143:2677–2683. [PubMed] [Google Scholar]
113. Faé KC, et al. CXCL9/MIG mediates T cells recruitment to valvular tissue lesions of chronic rheumatic heart disease patients. Inflammation. 2013;36:800–811. [PMC free article] [PubMed] [Google Scholar]
114. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;29:8175–8178. [PMC free article] [PubMed] [Google Scholar]
115. Martins TB, et al. Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol. 2008;20:445–452. [PubMed] [Google Scholar]
116. Tandon R, et al. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol. 2013;10:171–177. [PubMed] [Google Scholar]
117. Dinkla K, et al. Streptococcus pyogenes recruits collagen via surface-bound fibronectin: a novel colonization and immune evasion mechanism. Mol Microbiol. 2003;47:861–869. [PubMed] [Google Scholar]
118. Lukomski S, et al. Identification and characterization of the scl gene encoding a group A Streptococcus extracellular protein virulence factor with similarity to human collagen. Infect Immun. 2000;68:6542–6553. [PMC free article] [PubMed] [Google Scholar]
119. Lukomski S, et al. Identification and characterization of a second extracellular collagen-like protein made by group A Streptococcus: control of production at the level of translation. Infect Immun. 2001;69:1729–1738. [PMC free article] [PubMed] [Google Scholar]
120. Galvin JE, et al. Induction of myocarditis and valvulitis in Lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol. 2002;160:297–306. This study of mAbs from human rheumatic carditis explain the mimicry between group A streptococcal antigens and the heart valves and myocardium. Specific cross-reactive antigens included the group A carbohydrate and α-helical proteins such as cardiac myosin in the myocardium and laminin in the endocardium of the valve. [PMC free article] [PubMed] [Google Scholar]
121. Chopra P, Narula J, Kumar AS, Sachdeva S, Bhatia ML. Immunohistochemical characterisation of Aschoff nodules and endomyocardial inflammatory infiltrates in left atrial appendages from patients with chronic rheumatic heart disease. Int J Cardiol. 1988;20:99–105. [PubMed] [Google Scholar]
122. Chopra P, Narula JP. Scanning electron microscope features of rheumatic vegetations in acute rheumatic carditis. Int J Cardiol. 1991;30:109–112. [PubMed] [Google Scholar]
123. Roberts S, et al. Immune mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis. 2001;183:507–511. [PubMed] [Google Scholar]
124. Aschoff L. Myocarditisfrage. Verh Dtsch Path Ges. 1906;8:46–53. [Google Scholar]
125. de O Martins C, et al. Distinct mitral valve proteomic profiles in rheumatic heart disease and myxomatous degeneration. Clin Med Insights Cardiol. 2014;8:79–86. [PMC free article] [PubMed] [Google Scholar]
126. Guilherme L, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol. 2000;12:1063–1074. [PubMed] [Google Scholar]
127. Guilherme L, et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol. 2004;165:1583–1591. [PMC free article] [PubMed] [Google Scholar]
128. Dileepan T, et al. Robust antigen specific Th27 T cell response to group A Streptococcus is dependent on IL-6 and intranasal route of infection. PLoS Pathog. 2011;7:e1002252. [PMC free article] [PubMed] [Google Scholar]
129. Pepper M, et al. Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells. Nat Immunol. 2010;11:83–89. [PMC free article] [PubMed] [Google Scholar]
130. Wang B, et al. Induction of TGFβ1 and TGFβ1-dependent predominant TH17 differentiation by group A streptococcal infection. Proc Natl Acad Sci USA. 2010;107:5937–5942. [PMC free article] [PubMed] [Google Scholar]
131. Bas HD, et al. A shift in the balance of regulatory T and T helper 17 cells in rheumatic heart disease. J Invest Med. 2014;62:78–83. [PubMed] [Google Scholar]
132. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–852. [PubMed] [Google Scholar]
133. Peck A, Mellins ED. Precarious balance: TH17 cells in host defense. Infect Immun. 2010;78:32–38. [PMC free article] [PubMed] [Google Scholar]
134. Guilherme L, et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation. 1995;92:415–420. [PubMed] [Google Scholar]
135. Kirvan CA, Galvin JE, Hilt S, Kosanke S, Cunningham MW. Identification of streptococcal M-protein cardiopathogenic epitopes in experimental autoimmune valvulitis. J Cardiovasc Transl Res. 2013;7:172–181. [PMC free article] [PubMed] [Google Scholar]
136. Veasy LG, Tani LY. A new look at acute rheumatic mitral regurgitation. Cardiol Young. 2005;15:568–577. [PubMed] [Google Scholar]
137. Jones TD. The diagnosis of rheumatic fever. J Am Med Assoc. 1944;126:481–484. [Google Scholar]
138. [No authors listed.]Jones Criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation. 1984;69:204A–208A. [PubMed] [Google Scholar]
139. [No authors listed.]Guidelines for the diagnosis of rheumatic fever Jones Criteria, 1992 update Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA. 1992;268:2069–2073. [PubMed] [Google Scholar]
140. [No authors listed.]Jones criteria (modified) for guidance in the diagnosis of rheumatic fever; report of the Committee on Standards and Criteria for programs of care. Circulation. 1956;13:617–620. [PubMed] [Google Scholar]
141. [No authors listed.]Jones Criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation. 1965;32:664–668. [PubMed] [Google Scholar]
142. Australia (ARF/RHD Writing Group), National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand.) Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease. 2nd. Menzies School of Health Research; 2012. [Google Scholar]
143. Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr. 1994;124:9–16. [PubMed] [Google Scholar]
144. Veasy LG, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med. 1987;316:421–427. [PubMed] [Google Scholar]
145. Vijayalakshmi I, Vishnuprabhu RO, Chitra N. The efficacy of echocardiographic criterions for the diagnosis of carditis in acute rheumatic fever. Cardiol Young. 2008;18:586–592. [PubMed] [Google Scholar]
146. Narula J, Kaplan EL. Echocardiographic diagnosis of rheumatic fever. Lancet. 2001;358:2000. [PubMed] [Google Scholar]
147. Abernethy M, et al. Doppler echocardiography and the early diagnosis of carditis in acute rheumatic fever. Aust N Z J Med. 1994;24:530–535. [PubMed] [Google Scholar]
148. Figueroa FE, et al. Prospective comparison of clinical and echocardiographic diagnosis of rheumatic carditis: long term follow up of patients with subclinical disease. Heart. 2001;85:407–410. [PMC free article] [PubMed] [Google Scholar]
149. Minich L, Tani LY, Pagotto LT. Doppler echocardiography distinguishes between physiologic and pathologic ‘silent’ mitral regurgitation in patients with rheumatic fever. Clin Cardiol. 1997;20:924–926. [PMC free article] [PubMed] [Google Scholar]
150. Padmavati S, Gupta V. Reappraisal of the Jones criteria: the Indian experience. N Z Med J. 1988;101:391–392. [PubMed] [Google Scholar]
151. Pereira BAF, et al. Jones Criteria and underdiagnosis of rheumatic fever. Indian J Pediatr. 2007;74:117–121. [PubMed] [Google Scholar]
152. National Heart Foundation of New Zealand & the Cardiac Society of Australia and New Zealand. Evidence-based, best practice New Zealand Guidelines for Rheumatic Fever 1 Diagnosis, Management and Secondary Prevention. National Heart Foundation of New Zealand; 2006. [Google Scholar]
153. National Heart Foundation of Australia (RF/RHD Guideline Development Working Group) & the Cardiac Society of Australia and New Zealand. Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease in Australia — an Evidence-Based Review. National Heart Foundation of New Zealand; 2006. [Google Scholar]
154. Okello E, et al. Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda. Cardiovasc J Afr. 2013;24:80–85. [PMC free article] [PubMed] [Google Scholar]
155. Singh PI, Carapetis JR, Buadromo EM, Samberkar PN, Steer AC. The high burden of rheumatic heart disease found on autopsy in Fiji. Cardiol Young. 2008;18:62–69. [PubMed] [Google Scholar]
156. Gordis L, Lilienfeld A, Rodriguez R. Studies in the epidemiology and preventability of rheumatic fever. I. Demographic factors and the incidence of acute attacks. J Chronic Dis. 1969;21:645–654. [PubMed] [Google Scholar]
157. Glover JA. Milroy lectures on the incidence of rheumatic diseases. Lancet. 1930;215:499–505. [Google Scholar]
158. Salmond C, Crampton P, Atkinson J. NZDep2006 Index of Deprivation. Department of Public Health; 2007. [Google Scholar]
159. Kerdemelidis M, Lennon DR, Arroll B, Peat B, Jarman J. The primary prevention of rheumatic fever. J Paediatr Child Health. 2010;46:534–548. [PubMed] [Google Scholar]
160. Irlam J, Mayosi BM, Engel M, Gaziano TA. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circul Cardiovasc Qual Outcomes. 2013;6:343–351. [PubMed] [Google Scholar]
161. Lennon D, Stewart J, Farrell E, Palmer A, Mason H. School-based prevention of acute rheumatic fever: a group randomized trial in New Zealand. Pediatr Infect Dis J. 2009;28:787–794. [PubMed] [Google Scholar]
162. LeMarechal F, Martnot A, Duhamel A, Pruvost I, Dubos F. Streptococcal pharyngitis in children: a meta-analysis of clinical decision rules and their clinical variables. BMJ Open. 2013;3:e001482. [PMC free article] [PubMed] [Google Scholar]
163. Catanzaro FJ, Rammelkamp CH, Jr, Chamovitz R. Prevention of rheumatic fever by treatment of streptococcal infections. N Engl J Med. 1958;259:53–57. [PubMed] [Google Scholar]
164. Bass JW, Crast FW, Knowles CR, Onufer CN. Streptococcal pharyngitis in children: A comparison of four treatment schedules with intramuscular penicillin G benzathine. JAMA. 1976;235:1112–1116. [PubMed] [Google Scholar]
165. Lennon DR, Farrell E, Martin DR, Stewart JM. Once-daily amoxicillin versus twice-daily penicillin V in group A β-haemolytic streptococcal pharyngitis. Arch Dis Child. 2008;93:474–478. [PubMed] [Google Scholar]
166. Clegg HW, et al. Treatment of streptococcal pharyngitis with once-daily compared with twice-daily amoxicillin: a noninferiority trial. Pediatr Infect Dis J. 2006;25:761–767. [PubMed] [Google Scholar]
167. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis. 2012;25:145–153. [PubMed] [Google Scholar]
168. Martin DR, Voss LM, Walker SJ, Lennon D. Acute rheumatic fever in Auckland, New Zealand: spectrum of associated group A streptococci different from expected. Pediatr Infect Dis J. 1994;13:264–269. [PubMed] [Google Scholar]
169. Williamson DA, et al. M-protein analysis of Streptococcus pyogenes isolates associated with acute rheumatic fever in New Zealand. J Clin Microbiol. 2015;53:3618–3620. [PMC free article] [PubMed] [Google Scholar]
170. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002;3:CD002227. [PMC free article] [PubMed] [Google Scholar]
171. Tompkins DG, Boxerbaum B, Liebman J. Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. Circulation. 1972;45:543–551. [PubMed] [Google Scholar]
172. Taranta A. Factors influencing recurrent rheumatic fever. Annu Rev Med. 1967;18:159–172. [PubMed] [Google Scholar]
173. Bland EF, Duckett Jones T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation. 1951;4:836–843. [PubMed] [Google Scholar]
174. Ash R. Rheumatic infection in childhood; 15 to 20 year follow-up. Am J Dis Child. 1948;76:46–52. [PubMed] [Google Scholar]
175. Wilson MG, Lubschez R. Longevity in rheumatic fever; based on the experience of 1,042 children observed over a period of 30 years. J Am Med Assoc. 1948;138:794–798. [PubMed] [Google Scholar]
176. Lue HC, Wu MH, Wang JK, Wu FF, Wu YN. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr. 1994;125:812–816. [PubMed] [Google Scholar]
177. Spinetto H, Lennon D, Horsburgh M. Rheumatic fever recurrence prevention: a nurse-led programme of 28-day penicillin in an area of high endemnicity. J Paediatr Child Health. 2011;47:228–234. [PubMed] [Google Scholar]
178. Tubridy-Clark M, Carapetis JR. Subclinical carditis in rheumatic fever: a systematic review. Int J Cardiol. 2007;119:54–58. [PubMed] [Google Scholar]
179. Araujo FD, Goulart EM, Meira ZM. Prognostic value of clinical and Doppler echocardiographic findings in children and adolescents with significant rheumatic valvular disease. Ann Pediatr Cardiol. 2012;5:120–126. [PMC free article] [PubMed] [Google Scholar]
180. Pekpak E, et al. Rheumatic silent carditis: echocardiographic diagnosis and prognosis of long-term follow up. Pediatr Int. 2013;55:685–689. [PubMed] [Google Scholar]
181. Remenyi B, et al. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol. 2013;10:284–292. [PubMed] [Google Scholar]
182. Pelajo CF, Lopez-Benitez JM, Torres JM, de Oliveira SK. Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever. Pediatr Rheumatol Online J. 2010;8:22. [PMC free article] [PubMed] [Google Scholar]
183. Tadele H, Mekonnen W, Tefera E. Rheumatic mitral stenosis in children: more accelerated course in sub-Saharan patients. BMC Cardiovasc Disord. 2013;13:95. [PMC free article] [PubMed] [Google Scholar]
184. Heart Foundation of New Zealand. New Zealand guidelines for rheumatic fever: diagnosis, management and secondary prevention of acute rheumatic fever and rheumatic heart disease: 2014 update. Heart Foundation of New Zealand; 2014. [online], //www.heartfoundation.org.nz/uploads/HF2227A_Rheumatic_Fever_Guideline_v3.pdf. This is an evidence-based guideline highlighting the importance of hospitalization for patients with ARF to facilitate echocardiography, education and commencement of secondary prophylaxis. [Google Scholar]
185. Nishimura RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521–e643. [PubMed] [Google Scholar]
186. Saxena A, et al. Prevalence and outcome of subclinical rheumatic heart disease in India: the RHEUMATIC (Rheumatic Heart Echo Utilisation and Monitoring Actuarial Trends in Indian Children) study. Heart. 2011;97:2018–2022. [PubMed] [Google Scholar]
187. Webb RH, et al. Optimising echocardiographic screening for rheumatic heart disease in New Zealand: not all valve disease is rheumatic. Cardiol Young. 2011;21:436–443. [PubMed] [Google Scholar]
188. Paar JA, et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am J Cardiol. 2010;105:1809–1814. [PMC free article] [PubMed] [Google Scholar]
189. Bhaya M, Panwar S, Beniwal R, Panwar RB. High prevalence of rheumatic heart disease detected by echocardiography in school children. Echocardiography. 2010;27:448–453. [PubMed] [Google Scholar]
190. Carapetis JR, et al. Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. Nat Clin Pract Cardiovasc Med. 2008;5:411–417. [PubMed] [Google Scholar]
191. Marijon E, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007;357:470–476. [PubMed] [Google Scholar]
192. Beaton A, et al. Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren. Circulation. 2012;125:3127–3132. [PubMed] [Google Scholar]
193. Roberts K, Colquhoun S, Steer A, Remenyi B, Carapetis J. Screening for rheumatic heart disease: current approaches and controversies. Nat Rev Cardiol. 2013;10:49–58. [PubMed] [Google Scholar]
194. Miranda LP, Camargos PA, Torres RM, Meira ZM. Prevalence of rheumatic heart disease in a public school of Belo Horizonte. Arq Bras Cardiol. 2014;103:89–97. [PMC free article] [PubMed] [Google Scholar]
195. Roberts KV, Brown AD, Maguire GP, Atkinson DN, Carapetis JR. Utility of auscultatory screening for detecting rheumatic heart disease in high-risk children in Australia’s Northern Territory. Med J Aust. 2013;199:196–199. [PubMed] [Google Scholar]
196. Zuhlke L, Mayosi BM. Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of impact on prognosis. Curr Cardiol Rep. 2013;15:343. [PubMed] [Google Scholar]
197. Remenyi B, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease — an evidence-based guideline. Nat Rev Cardiol. 2012;9:297–309. This article provides guidance on the Doppler and two-dimensional echocardiographic findings that are consistent with RHD. The criteria are based on consensus international expert opinion and available evidence and have been crucial for the field in standardizing diagnosis across centres. [PMC free article] [PubMed] [Google Scholar]
198. Roberts K, et al. Echocardiographic screening for rheumatic heart disease in high and low risk Australian children. Circulation. 2014;129:1953–1961. [PubMed] [Google Scholar]
199. Beaton A, et al. The utility of handheld echocardiography for early diagnosis of rheumatic heart disease. J Am Soc Echocardiogr. 2014;27:42–49. [PubMed] [Google Scholar]
200. Beaton A, et al. Utility of handheld echocardiography for early rheumatic heart disease diagnosis: a field study. Eur Heart J Cardiovasc Imaging. 2015;16:475–482. [PMC free article] [PubMed] [Google Scholar]
201. Tani LY. Echocardiographic screening for rheumatic heart disease. Circulation. 2014;129:1912–1913. [PubMed] [Google Scholar]
202. Colquhoun SM, et al. Echocardiographic screening in a resource poor setting: borderline rheumatic heart disease could be a normal variant. Int J Cardiol. 2014;173:284–289. [PubMed] [Google Scholar]
203. Beaton A, et al. Latent rheumatic heart disease: outcomes 2 years after echocardiographic detection. Pediatr Cardiol. 2014;35:1259–1267. [PubMed] [Google Scholar]
204. Bhaya M, Beniwal R, Panwar S, Panwar RB. Two years of follow-up validates the echocardiographic criteria for the diagnosis and screening of rheumatic heart disease in asymptomatic populations. Echocardiography. 2011;28:929–933. [PubMed] [Google Scholar]
205. Colquhoun SM, et al. Pilot study of nurse-led rheumatic heart disease echocardiography screening in Fiji — a novel approach in a resource-poor setting. Cardiol Young. 2013;23:546–552. [PubMed] [Google Scholar]
206. Kane A, et al. Echocardiographic screening for rheumatic heart disease: age matters. Int J Cardiol. 2013;168:888–891. [PubMed] [Google Scholar]
207. Manji RA, et al. Cost-effectiveness analysis of rheumatic heart disease prevention strategies. Expert Rev Pharmacoecon Outcomes Res. 2013;13:715–724. [PubMed] [Google Scholar]
208. Catanzaro FJ, et al. The role of the streptococcus in the pathogenesis of rheumatic fever. Am J Med. 1954;17:749–756. [PubMed] [Google Scholar]
210. Carter ME, Bywaters EG, Thomas GT. Rheumatic fever treated with penicillin in bactericidal dosage for six weeks. Report of a small controlled trial. Br Med J. 1962;1:965–967. [PMC free article] [PubMed] [Google Scholar]
211. Mortimer EA, Jr, et al. The effect of penicillin on acute rheumatic fever and valvular heart disease. N Engl J Med. 1959;260:101–112. [PubMed] [Google Scholar]
212. Markowitz M, Gordis L. Rheumatic fever. Major Probl Clin Pediatr. 1972;11:1–309. [PubMed] [Google Scholar]
213. Albert DA, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore) 1995;74:1–12. [PubMed] [Google Scholar]
214. Cilliers A, Manyemba J, Adler AJ, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev. 2012;6:CD003176. This systematic review confirms that there is no evidence-based medical treatment that alters the outcome of carditis in ARF. [PubMed] [Google Scholar]
215. Rheumatic Fever Working Party of the Medical Research Council of Great Britain and the Subcommittee of Principal Investigators of the American Council on Rheumatic Fever and Congenital Heart Disease, American Heart Association. Treatment of acute rheumatic fever in children a co-operative clinical trial of A.C.T.H., cortisone and aspirin. Circulation. 1955;11:343–377. [PMC free article] [PubMed] [Google Scholar]
216. Voss LM, et al. Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial. Circulation. 2001;103:401–406. [PubMed] [Google Scholar]
217. Azevedo PM, Pereira RR, Guilherme L. Understanding rheumatic fever. Rheumatol Int. 2012;32:1113–1120. [PubMed] [Google Scholar]
218. Nishimura RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–e185. This article provides a clear guideline outlining that indications for cardiac surgery in adults are based on extensive evidence of management of adults with valvular heart disease. [PubMed] [Google Scholar]
219. Anderson Y, Wilson N, Nicholson R, Finucane K. Fulminant mitral regurgitation due to ruptured chordae tendinae in acute rheumatic fever. J Paediatr Child Health. 2008;44:134–137. [PubMed] [Google Scholar]
220. Finucane K, Wilson N. Priorities in cardiac surgery for rheumatic heart disease. Glob Heart. 2013;8:213–220. [PubMed] [Google Scholar]
221. Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV. Persistent Sydenham’s chorea. Mov Disord. 1999;14:805–807. [PubMed] [Google Scholar]
222. Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. 2002;24:73–76. [PubMed] [Google Scholar]
223. Daoud AS, Zaki M, Shakir R, al-Saleh Q. Effectiveness of sodium valproate in the treatment of Sydenham’s chorea. Neurology. 1990;40:1140–1141. [PubMed] [Google Scholar]
224. Pena J, Mora E, Cardozo J, Molina O, Montiel C. Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham’s chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr. 2002;60:374–377. [PubMed] [Google Scholar]
225. Hashkes PJ, et al. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial. J Pediatr. 2003;143:399–401. [PubMed] [Google Scholar]
226. Uziel Y, et al. The use of naproxen in the treatment of children with rheumatic fever. J Pediatr. 2000;137:269–271. [PubMed] [Google Scholar]
227. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet. 2005;366:155–168. [PubMed] [Google Scholar]
228. World Health Organization. Report of a WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease. WHO; 2001. [Google Scholar]
229. Wilson N, Voss LM, Neutze JM. In: Proceedings of the Second World Congress of Pediatric Cardiology and Cardiacsurgery. Imai Y, Momma K, editors. Futura Publishing Co; 1998. pp. 971–972. [Google Scholar]
230. Walsh WF. Medical management of chronic rheumatic heart disease. Heart Lung Circ. 2010;19:289–294. [PubMed] [Google Scholar]
231. Nishimura RA, et al. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:676–685. [PubMed] [Google Scholar]
232. Cheung MM, Sullivan ID, de Leval MR, Tsang VT, Redington AN. Optimal timing of the Ross procedure in the management of chronic aortic incompetence in the young. Cardiol Young. 2003;13:253–257. [PubMed] [Google Scholar]
233. Gentles TL, et al. Normalized end-systolic volume and pre-load reserve predict ventricular dysfunction following surgery for aortic regurgitation independent of body size. JACC Cardiovasc Imaging. 2012;5:626–633. [PubMed] [Google Scholar]
234. Remenyi B, et al. Improved long-term survival for rheumatic mitral valve repair compared to replacement in the young. World J Pediatr Congenit Heart Surg. 2013;4:155–164. [PubMed] [Google Scholar]
235. Gentles TL, Finucane AK, Remenyi B, Kerr AR, Wilson NJ. Ventricular function before and after surgery for isolated and combined regurgitation in the young. Ann Thorac Surg. 2015;100:1383–1389. [PubMed] [Google Scholar]
236. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373:1382–1394. [PubMed] [Google Scholar]
237. DiBardino DJ, et al. Four decades of experience with mitral valve repair: analysis of differential indications, technical evolution, and long-term outcome. J Thorac Cardiovasc Surg. 2010;139:76–83. discussion 83-74. [PubMed] [Google Scholar]
238. Antunes MJ, Magalhaes MP, Colsen PR, Kinsley RH. Valvuloplasty for rheumatic mitral valve disease. A surgical challenge. J Thorac Cardiovasc Surg. 1987;94:44–56. [PubMed] [Google Scholar]
239. Sadler L, et al. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG. 2000;107:245–253. [PubMed] [Google Scholar]
240. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–1409. [PubMed] [Google Scholar]
241. do Nascimento Moraes A. Health related quality of life in children with rheumatic heart diseases: reliablityof the Brazilian version of the pediatric quality of life inventory cardiac module scale. Health Qual Life Outcomes. 2013;11:198. [PMC free article] [PubMed] [Google Scholar]
242. Arafa M, Zaher S, El-Dowaty A, Moneeb D. Quality of life among parents of children with heart disease. Health Qual Life Outcomes. 2008;6:91. [PMC free article] [PubMed] [Google Scholar]
243. Essaway M, Bahgat Z, Kassem H. Health-related quality of life of school-aged children with rheumatic fever. J Egypt Publ Health Associ. 2010;85:205–222. [PubMed] [Google Scholar]
244. Wark E, Hodder Y, Woods C, Maguie G. Patient and health-care impact of a pilot rheumatic heart disease screening program. J Paediatr Child Health. 2013;49:297–302. [PubMed] [Google Scholar]
245. Pilgrim T, et al. Protocol for a population-based study of rheumatic heart disease prevalence and cardiovascular outcomes among school children in Nepal. BMJ Open. 2012;2:e001320. [PMC free article] [PubMed] [Google Scholar]
246. Koech M, Ngeno T. Perception of parents whose children have rheumatic heart disease at a referral hospital, Kenya. Bas Res J Med Clin Sci. 2014;3:67–73. [Google Scholar]
247. Atnafe L. Thesis. Addis Ababa University; 2011. The Experience of Married Women with Rheumatic Heart Disease. [Google Scholar]
248. Harrington Z, Thomas D, Currie B, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust. 2006;184:514–517. [PubMed] [Google Scholar]
249. Petricca K, Mamo Y, Haileamlk A, Seid E, Parry E. Barriers to effective follow-up treatment for rheumatic heart disease in Jimma, Ethiopia: a grounded theory analysis of the patient experience. Ethiopian J Health Sci. 2009;19:39–44. [Google Scholar]
250. Johnson TD, et al. The 5 × 5 path towards rheumatic heart disease control: outcomes from the third rheumatic heart disease forum. Glob Heart. 2014;10:75–78. [PubMed] [Google Scholar]
251. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol. 2010;30:17–23. [PubMed] [Google Scholar]
252. Mayosi B, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S Afr Med J. 2006;96:246. [PubMed] [Google Scholar]
253. Karthikeyan G, et al. Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. Am Heart J. 2012;163:535–540. [PMC free article] [PubMed] [Google Scholar]
255. Nishimura RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2438–2488. [PubMed] [Google Scholar]
256. Moran M, et al. Neglected disease research and development: how much are we really spending? PLoS Med. 2009;6:e30. [PMC free article] [PubMed] [Google Scholar]
257. Dale JB, et al. Group A streptococcal vaccines: paving a path for accelerated development. Vaccine. 2013;31:B216–B222. [PubMed] [Google Scholar]
258. Guerino MT, et al. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine. 2011;29:8250–8256. [PubMed] [Google Scholar]
259. Engel ME, Stander R, Vogel J, Adeyemo AA, Mayosi BM. Genetic susceptibility to acute rheumatic fever: a systematic review and meta-analysis of twin studies. PLoS ONE. 2011;6:e25326. [PMC free article] [PubMed] [Google Scholar]
260. Fae KC, et al. PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular tissue, are the target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients. J Autoimmun. 2008;31:136–141. [PubMed] [Google Scholar]
261. Gao G, et al. Identification of altered plasma proteins by proteomic study in valvular heart diseases and the potential clinical significance. PLoS ONE. 2013;8:e72111. [PMC free article] [PubMed] [Google Scholar]
262. Ramakrishnan S, et al. Prevalence of rheumatic heart disease: has it declined in India? Natl Med J India. 2009;22:72–74. [PubMed] [Google Scholar]